RT Journal Article SR Electronic T1 Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy JF Cancer Genomics - Proteomics JO Cancer Genomics Proteomics FD International Institute of Anticancer Research SP 1 OP 7 VO 7 IS 1 A1 GEORG HOLGERSSON A1 SIMON EKMAN A1 JOHAN REIZENSTEIN A1 MICHAEL BERGQVIST A1 FREDRIK PONTÉN A1 MATTIAS UHLÉN A1 KRISTINA MAGNUSSON A1 PALLAVI JONNALAGADDA A1 ANNA ASPLUND A1 SARA STRÖMBERG A1 ARNE LINDER A1 ERIK BLOMQUIST A1 MARTIN LILJEHOLM A1 BRITTA LÖDÉN A1 KARIN HELLSTRÖM A1 STEFAN BERGSTRÖM YR 2010 UL http://cgp.iiarjournals.org/content/7/1/1.abstract AB Aim: To explore the usefulness of the expression of five potential cancer biomarkers in predicting outcome in patients with laryngeal cancer. Materials and Methods: In the present study, the Swedish National Cancer Registry databases were used to identify patients with laryngeal cancer diagnosed during the years 1978-2004 in the Uppsala-Örebro region and treated with radiotherapy. The expression of Ki-67, MutS homolog 2, (MSH2), p53, B-cell CLL/lymphoma 2 (Bcl-2) and cyclin D1 in the cancer cells was assessed immunohistochemically using tissue microarrays (TMAs) and its predicitve value on survival and relapse was analyzed using Cox regression models. Results: A total of 39 patients were included in the present study. Nuclear MSH2 staining was statistically significantly correlated to Ki-67 expression (p=0.022). However, univariate and multivariate Cox analyses showed no statistically significant association between the expression of the investigated biomarkers and overall survival or relapse. Conclusion: The present exploratory study does not show any significant predictive value of the biomarkers examined with respect to survival or relapse. However, with larger patient cohorts, we believe that protein profiling using TMAs and immunohistochemistry is a feasible strategy for prognostic and predictive biomarker screening in laryngeal cancer. Copyright© 2010 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved